EMA begins analyzing Bavarian Nordic's vaccine against monkeypox

Prior to deciding on a shared European vaccine supply purchase, the European Medicines Agency has begun analyzing the Danish firm’s smallpox vaccine against monkeypox.

Photo: Lukas Barth/Reuters/Ritzau Scanpix

The European Medicines Agency (EMA) has begun a risk/benefit analysis of using Danish biotech firm Bavarian Nordic’s smallpox vaccine against monkeypox, according to a press release from Sweden’s prime minister’s office.

According to the statement, the analysis will act as guidelines in connection with deciding a shared European vaccine supply purchase.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs